Calliditas Therapeutics (CALT)
(Real Time Quote from BATS)
$19.15 USD
+0.65 (3.51%)
Updated Apr 25, 2024 12:51 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Calliditas Therapeutics AB Sponsored ADR [CALT]
Reports for Purchase
Showing records 1 - 20 ( 25 total )
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CALT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Potential Transformative Approvals Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Near-Term Competition Further Alleviated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Not All Proteinuria Reductions Are the Same; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Slower Than Expected Nefecon Growth; Lower PT to $50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Developing Innovative Treatment for Orphan Renal and Hepatic Diseases; Initiate With Buy and a $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Thoughts Post TARPEYO Approval; Model Update; Raising PT to $62
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Nefecon, Now TARPEYO, Is Approved As the First Drug Indicated For IgAN
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Nefecon PDUFA Right Around the Corner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
PDUFA Extension Is Not Thesis Changing for Nefecon
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
We Remain Buyers Heading into Nefecon PDUFA; 2Q21 Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Strong European Commercial Partnership Is Built Ahead of Potential Nefecon Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Building Pipeline on NOX Inhibition Platform; Setanaxib Offers Potential Upside
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E